| 言語 |
英語
|
| 著者 |
Uemura Naomi
Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba, Japan
Haruma Ken
Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan
Yao Takashi
4 Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan
Kushima Ryoji
Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital, Shiga, Japan
Kanoo Tatsuhiro
Takeda Pharmaceutical Co., Ltd, Osaka, Japan
|
| 主題 | erosive esophagitis; gastric mucosa; lansoprazole; long-term safety; vonoprazan; K+ competitive channel inhibitor; neoplasia
|
| 掲載誌名 |
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY
|
| 巻 | 11
|
| 開始ページ | 51
|
| 終了ページ | 56
|
| ISSN | 1178-7023
|
| 発行日 | 2018
|
| DOI | |
| PubMed ID | |
| 出版者 | DOVE MEDICAL PRESS LTD
|
| 資料タイプ |
学術雑誌論文
|
| 部局 |
医学部
|
| 備考 | This study is funded by Takeda Pharmaceutical Co., Ltd. Takeda Pharmaceutical Co., Ltd has been involved in the planning and design of this study, and has contributed to the development and approval of the present manuscript. The final decision to submit the paper, however, lay directly with the authors. The authors acknowledge all patients who are participating in this study and their families, as well as all staff at all investigational sites. The authors thank Kouji Miyata (Takeda Pharmaceutical Co., Ltd Japan) for critical review of the manuscript and suggestions for improvement. The authors also acknowledge Rachel Moir of FireKite (an Ashfield company, part of UDG Healthcare plc), who provided medical writing assistance during the development of this manuscript, which was funded by Takeda Pharmaceutical Co., Ltd and complied with Good Publication Practice 3 ethical guidelines.
|
